Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

ly there is no marketed treatment for DGF; when DGF is diagnosed the patient is supported with dialysis and other supportive care.

The investigational drug candidate QPI-1002 is a siRNA designed to temporarily inhibit the expression of the pro-apoptotic gene, p53. This siRNA is based on Quark's proprietary, patented therapeutic concept of temporarily inhibiting the expression of p53 to protect normal cells from acute injury. QPI-1002 is a chemically modified siRNA discovered by Quark with structure covered under licenses from Silence Therapeutics and from Alnylam Pharmaceuticals. QPI-1002 was the first systemically administered siRNA in a human clinical study.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. QPI-1007, which is a siRNA that utilizes a novel siRNA structure developed by Quark and is being evaluated in advanced IND-e
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 2014 The Cadence Fitness & Health Center has ... Medical Fitness Association, a non-profit organization assisting medically integrated ... The Cadence Fitness & Health Center is the only ... in the Chicagoland area. "The certification means ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... April 2, 2012  Smith Medical Partners, the specialty ... an exclusive logistics and cold chain services agreement ... ), a health sciences and regenerative medicine company, ... Excellagen™.  Excellagen is a professional-use, syringe-based wound care ...
... 2012   Sunpeaks Ventures, Inc. (OTCBB: SNPK) ... its wholly owned subsidiary Healthcare Distribution Specialists, LLC ... now an authorized product at Winn-Dixie. Clotamin will ... Florida starting in May 2012. Winn-Dixie ...
Cached Medicine Technology:Smith Medical Partners Announces Logistics Agreement for Cardium's National Distribution of Excellagen™ 2Smith Medical Partners Announces Logistics Agreement for Cardium's National Distribution of Excellagen™ 3Sunpeaks Ventures Announces Clotamin to Be Sold at Winn-Dixie Locations in South Florida 2
(Date:4/23/2014)... mounts showing the potential health benefits of probiotics, antioxidants ... taking supplements. And the chemical industry is getting in ... effects could deter growth, so the industry is responding ... to the cover story in Chemical & Engineering ... American Chemical Society. , Melody M. Bomgardner, a senior ...
(Date:4/23/2014)... A team of scientists led by a researcher from ... the National University of Singapore has identified the cancer ... opens up the possibility of developing new drugs for ... cancers. , The research group, led by Dr Chan ... for the first time that a cancer-specific variant of ...
(Date:4/23/2014)... may prevent the depletion of self-control, according to research ... the Association for Psychological Science. , Self-control can be ... focus attention on a boring textbook are hard things ... this difficulty: Exerting self-control for a long period seems ... subsequent tasks. , "It is as if self-control is ...
(Date:4/22/2014)... Government and industry leaders visited the New Jersey ... President Joel S. Bloom for the launch of ... corporation that provides a new model for business ... higher education assets and investment. U.S. Senator Cory ... CEO Joe Taylor, New Jersey Lieutenant Governor Kim ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3
... from malaria-prone Garo Hills region, Meghalaya Health mininster E D ... // ,Marak, who returned from the Garo hills ... malaria this morning, his son told PTI., ,The Health ... two-day tour to West Garo Hills district town Tura., ...
... "Tobacco Kills/Smoking Kills" -- such health warnings would be ... sellers would attract stringent penalty including imprisonment. // ... packages include "Skull and Bones Sign" or a pictorial ... message., ,The Health and Family Welfare Ministry headed ...
... of surgeries - instruments, surgical sponges, etc tucked away ... resulting in post-surgery complications and even death of ... thousand cases are unwitting recipients of such medical mistakes. ... nicknamed as the 'magic wand' which will ensure surgeons ...
... after giving birth, says nutritionist, Sarah Keogh. Irish mothers are ... aspiring for an hour glass figure soon after child birth, ... mother and the child. ,Infact, she advises, that ... building nutrition levels in both the mother and the ...
... Victoria Metcalf is out to delve into the Antarctic ... the genetic filter technology// to understand how fish actually ... of the existing connection between fat metabolism and heart ... fat for fuel, unlike humans who get the energy ...
... The Australian Medical Association (AMA) has cautioned the Federal ... president, Dr Mukesh Haikerwal said that almost 30 per cent of ... many of them are due for retirement over the next few ... strive to extend the stay of the GPs in the work ...
Cached Medicine News:
... The Corkscrew II is a 5 mm suture ... a cancellous screw thread design for maximum pull-out ... individual eyelets to minimize the possibility of locking ... tied. The vertical laser mark on the distal ...
The Duet EnCompass Pelvic Floor Diagnostic System is the only equipment specifically designed to perform urodynamics, anorectal manometry, EMG and pudendal nerve latency studies on a single software ...
... is simple: to provide better care for your ... with lower urinary tract symptoms (LUTS) includes urodynamics ... due to increases in reimbursement, it now makes ... you are sending them to someone who does ...
... II (fully threaded) is a 5.5 mm ... inserted flush with the cortical bone surface ... The full thread design substantially improves pull-out ... eyelets. Especially advantageous when poor quality bone ...
Medicine Products: